Swedencare Valuation

Q: What is the Fair Price of SECARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SECARE (SEK40.52) is trading below our estimate of [[fair value]] (SEK156.38)

Is SECARE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SECARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SECARE (SEK40.52) is trading below our estimate of fair value (SEK156.38)

Significantly Below Fair Value: SECARE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SECARE?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for SECARE. This is calculated by dividing SECARE's market cap by their current preferred multiple.
What is SECARE's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 6.44b

SECARE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.2x
Enterprise Value/EBITDA	15.4x
PEG Ratio	1.5x

Price to Earnings Ratio vs Peers

How does SECARE's PE Ratio compare to its peers?

The above table shows the PE ratio for SECARE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	76.3x
CAMX Camurus	167.5x	75.3%	SEK 37.4b
MCAP MedCap	35.3x	n/a	SEK 7.5b
BIOG B BioGaia	26.9x	7.6%	SEK 10.8b
BONEX Bonesupport Holding	75.4x	31.2%	SEK 21.8b
SECARE Swedencare	84.6x	55.7%	SEK 6.4b

Price-To-Earnings vs Peers: SECARE is expensive based on its Price-To-Earnings Ratio (84.6x) compared to the peer average (76.3x).

Price to Earnings Ratio vs Industry

How does SECARE's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	68.6%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	68.6%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: SECARE is expensive based on its Price-To-Earnings Ratio (84.6x) compared to the European Pharmaceuticals industry average (23.2x).

Price to Earnings Ratio vs Fair Ratio

What is SECARE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SECARE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	84.6x
Fair PE Ratio	76.4x

Price-To-Earnings vs Fair Ratio: SECARE is expensive based on its Price-To-Earnings Ratio (84.6x) compared to the estimated Fair Price-To-Earnings Ratio (76.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SECARE forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	SEK 40.52	SEK 61.50 +51.8%	4.1%	SEK 64.00	SEK 59.00	n/a	2
Oct ’25	SEK 43.64	SEK 63.00 +44.4%	1.6%	SEK 64.00	SEK 62.00	n/a	2
Sep ’25	SEK 40.74	SEK 63.00 +54.6%	1.6%	SEK 64.00	SEK 62.00	n/a	2
Aug ’25	SEK 44.98	SEK 63.00 +40.1%	1.6%	SEK 64.00	SEK 62.00	n/a	2
Jul ’25	SEK 59.00	SEK 67.00 +13.6%	4.5%	SEK 70.00	SEK 64.00	n/a	2
Jun ’25	SEK 59.20	SEK 67.00 +13.2%	4.5%	SEK 70.00	SEK 64.00	n/a	2
May ’25	SEK 56.60	SEK 67.00 +18.4%	4.5%	SEK 70.00	SEK 64.00	n/a	2
Apr ’25	SEK 63.94	SEK 68.00 +6.3%	5.9%	SEK 72.00	SEK 64.00	n/a	2
Mar ’25	SEK 55.10	SEK 68.00 +23.4%	5.9%	SEK 72.00	SEK 64.00	n/a	2
Feb ’25	SEK 62.18	SEK 59.50 -4.3%	7.6%	SEK 64.00	SEK 55.00	n/a	2
Jan ’25	SEK 60.96	SEK 50.00 -18.0%	10.0%	SEK 55.00	SEK 45.00	n/a	2
Dec ’24	SEK 58.92	SEK 50.00 -15.1%	10.0%	SEK 55.00	SEK 45.00	n/a	2
Nov ’24	SEK 44.00	SEK 50.00 +13.6%	10.0%	SEK 55.00	SEK 45.00	n/a	2
Oct ’24	SEK 40.86	SEK 49.50 +21.1%	9.1%	SEK 54.00	SEK 45.00	SEK 43.64	2
Sep ’24	SEK 46.90	SEK 49.50 +5.5%	9.1%	SEK 54.00	SEK 45.00	SEK 40.74	2
Aug ’24	SEK 46.07	SEK 44.50 -3.4%	21.3%	SEK 54.00	SEK 35.00	SEK 44.98	2
Jul ’24	SEK 38.01	SEK 44.50 +17.1%	21.3%	SEK 54.00	SEK 35.00	SEK 59.00	2
Jun ’24	SEK 44.40	SEK 44.50 +0.2%	21.3%	SEK 54.00	SEK 35.00	SEK 59.20	2
May ’24	SEK 32.60	SEK 42.00 +28.8%	31.0%	SEK 55.00	SEK 29.00	SEK 56.60	2
Apr ’24	SEK 25.47	SEK 47.50 +86.5%	26.3%	SEK 60.00	SEK 35.00	SEK 63.94	2
Mar ’24	SEK 26.74	SEK 47.25 +76.7%	27.0%	SEK 60.00	SEK 34.50	SEK 55.10	2
Feb ’24	SEK 36.28	SEK 54.75 +50.9%	37.0%	SEK 75.00	SEK 34.50	SEK 62.18	2
Jan ’24	SEK 30.75	SEK 58.00 +88.6%	29.3%	SEK 75.00	SEK 41.00	SEK 60.96	2
Dec ’23	SEK 34.88	SEK 58.00 +66.3%	29.3%	SEK 75.00	SEK 41.00	SEK 58.92	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.